Magali Olivier

14.0k citations

68 papers · 9.4k indexed · 6 hit papers · h-index 37

Molecular Biology top 1%
Oncology top 0.2%
Cancer Research top 0.2%
Pulmonary and Respiratory Medicine top 2%
Genetics top 2%

Co-authors: Pierre Hainaut Monica Hollstein Audrey Petitjean Rosalind A. Eeles Curtis C. Harris Chikashi Ishioka Shunsuke Kato Sean V. Tavtigian
Topics: Cancer-related Molecular Pathways (43 papers)Cancer Genomics and Diagnostics (25 papers)Epigenetics and DNA Methylation (9 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Journal of Biological Chemistry Journal of Clinical Oncology Nature reviews. Cancer
Partner nations: France United States United Kingdom

In The Last Decade

Magali Olivier

68 papers receiving 9.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use

2009 1.5k citations Magali Olivier, Monica Hollstein et al. Cold Spring Harbor Perspectives in Biology profile →
Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

2007 1.2k citations Audrey Petitjean, Ewy A. Mathé et al. Human Mutation profile →
The IARC TP53 database: New online mutation analysis and recommendations to users

2002 980 citations Magali Olivier, Monica Hollstein et al. Human Mutation profile →
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers

2002 815 citations Magali Olivier, Pierre Hainaut et al. Oncogene profile →
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

2007 689 citations Audrey Petitjean, Maria Isabel Achatz et al. Oncogene profile →
TP53Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data

2016 536 citations Liacine Bouaoun, Maude Ardin et al. Human Mutation profile →

Peers

Countries citing papers authored by Magali Olivier

Since Specialization

Citations

This map shows the geographic impact of Magali Olivier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Magali Olivier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Magali Olivier more than expected).

Fields of papers citing papers by Magali Olivier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Magali Olivier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Magali Olivier. The network helps show where Magali Olivier may publish in the future.

Co-authorship network of co-authors of Magali Olivier

This figure shows the co-authorship network connecting the top 25 collaborators of Magali Olivier. A scholar is included among the top collaborators of Magali Olivier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Magali Olivier. Magali Olivier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute 2022 ·Cell Death and Differentiation ·Kelvin C. de Andrade,(unknown),(unknown),Chimene Kesserwan,James J. Manfredi,(unknown),(unknown),Jiří Zavadil,Lei Zhou,Magali Olivier,Megan N. Frone,(unknown),William J.R. Longabaugh,Christian P. Kratz,David Malkin,Pierre Hainaut,Sharon A. Savage	80
2	The International Collaboration for Cancer Classification and Research 2020 ·International Journal of Cancer ·Ian A. Cree,(unknown),Jiří Zavadil,James McKay,Magali Olivier,Zisis Kozlakidis,Alexander J. Lazar,Chris Hyde,Stefan Holdenrieder,Ros Hastings,Nasir Rajpoot,Arnaud de la Fouchardière,Brian Rous,Jean C. Zenklusen,Nicola Normanno,Richard L. Schilsky,(unknown)	35
3	Experimental and pan-cancer genome analyses reveal widespread contribution of acrylamide exposure to carcinogenesis in humans 2019 ·Genome Research ·(unknown),Alvin Wei Tian Ng,Maude Ardin,Mona I. Churchwell,(unknown),Claire Renard,Stéphanie Villar,Vincent Cahais,Alexis Robitaille,Liacine Bouaoun,Adriana Heguy,Kathryn Z. Guyton,Martha R. Stampfer,James McKay,Monica Hollstein,Magali Olivier,Steve Rozen,Frederick A. Beland,Michael Korenjak,Jiří Zavadil	59
4	Improved, ACMG-compliant, in silico prediction of pathogenicity for missense substitutions encoded by TP53 variants 2018 ·Human Mutation ·Cristina Fortuño,Paul A. James,Erin L. Young,Bing Feng,Magali Olivier,Tina Pesaran,Sean V. Tavtigian,Amanda B. Spurdle	27
5	Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing 2017 ·Oncogene ·(unknown),Maude Ardin,Annette Weninger,(unknown),Sarah Barrin,Stéphanie Villar,Magali Olivier,Tomáš Stopka,Zdenko Herceg,Monica Hollstein,Jiří Zavadil,Michael Korenjak	8
6	Genome-scale mutational signatures of aflatoxin in cells, mice, and human tumors 2017 ·Genome Research ·Mi Huang,Willie Yu,(unknown),Maude Ardin,Apinya Jusakul,Alvin Wei Tian Ng,Arnoud Boot,Behnoush Abedi‐Ardekani,Stéphanie Villar,Swe Swe Myint,(unknown),Song Ling Poon,Adriana Heguy,Magali Olivier,Monica Hollstein,Patrick Tan,Bin Tean Teh,Kanaga Sabapathy,Jiří Zavadil,Steve Rozen	75
7	Intérêts de l’ADN circulant pour la prise en charge du cancer broncho-pulmonaire 2015 ·Revue de Pneumologie Clinique ·(unknown),Stéphanie Villar,Magali Olivier,S. Couraud	1
8	Circulating free DNA concentration is an independent prognostic biomarker in lung cancer 2015 ·European Respiratory Journal ·Claire Tissot,Anne‐Claire Toffart,Stéphanie Villar,Pierre-Jean Souquet,P. Merle,Denis Moro‐Sibilot,M. Pérol,Jiří Zavadil,Christian Brambilla,Magali Olivier,S. Couraud	99
9	Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues 2015 ·PLoS ONE ·Felipe Vaca‐Paniagua,Rosa María Álvarez-Gómez,Héctor Aquiles Maldonado-Martínez,Carlos Pérez‐Plasencia,Verónica Fragoso‐Ontiveros,(unknown),Luis A. Herrera,David Cantú de León,Enrique Bargalló‐Rocha,Alejandro Mohar,Geoffroy Durand,Nathalie Forey,Catherine Voegele,Maxime Vallée,Florence Le Calvez‐Kelm,James McKay,Maude Ardin,Stéphanie Villar,Jiří Zavadil,Magali Olivier	16
10	Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures 2013 ·Carcinogenesis ·Corinne Sagné,Virginie Marcel,Maria Bota,Ghyslaine Martel‐Planche,Alberto Nóbrega,Edenir Inêz Palmero,(unknown),Mathieu Boniol,Stéphan Vagner,David G. Cox,C. Savio Chan,Jean‐Louis Mergny,Magali Olivier,Patrícia Ashton‐Prolla,J. Hall,Pierre Hainaut,Maria Isabel Achatz	30
11	Prognostic value ofTP53,KRASandEGFRmutations in nonsmall cell lung cancer: the EUELC cohort 2012 ·European Respiratory Journal ·Chiara Scoccianti,Aurélien Vesin,(unknown),Magali Olivier,(unknown),Jean‐François Timsit,Luca Tavecchio,Christian Brambilla,John K. Field,Pierre Hainaut	82
12	Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop 2011 ·Cell Death and Differentiation ·Giovanni Blandino,Wolfgang Deppert,Pierre Hainaut,Arnold J. Levine,Guillermina Lozano,Magali Olivier,Varda Rotter,Klas G. Wiman,Moshe Oren	28
13	TP53 mutation p.R337H in gastric cancer tissues of a 12-year-old male child - evidence for chimerism involving a common mutant founder haplotype: case report 2011 ·BMC Cancer ·Edaise M. da Silva,Maria Isabel Achatz,Ghyslaine Martel‐Planche,André L. Montagnini,Magali Olivier,Patrícia Ashton‐Prolla,Pierre Hainaut,Fernando Augusto Soares	6
14	First International p53 Isoforms Meeting: ‘p53 isoforms through evolution: from identification to biological function’ 2010 ·Cell Death and Differentiation ·Virginie Marcel,Magali Olivier,Bertrand Mollereau,Pierre Hainaut,Jean‐Christophe Bourdon	9
15	TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Usebreakdown → 2009 ·Cold Spring Harbor Perspectives in Biology ·Magali Olivier,Monica Hollstein,Pierre Hainaut	1507
16	Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome 2009 ·Current Opinion in Oncology ·Edenir Inêz Palmero,Maria Isabel Achatz,Patrícia Ashton‐Prolla,Magali Olivier,Pierre Hainaut	64
17	Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databasebreakdown → 2007 ·Human Mutation ·Audrey Petitjean,Ewy A. Mathé,Shunsuke Kato,Chikashi Ishioka,Sean V. Tavtigian,Pierre Hainaut,Magali Olivier	1233
18	Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations 2006 ·Human Mutation ·Ewy A. Mathé,Magali Olivier,Shunsuke Kato,Chikashi Ishioka,Iosif I. Vaisman,Pierre Hainaut	19
19	TP53 mutations as biomarkers for cancer epidemiology in Latin America: Current knowledge and perspectives 2005 ·Mutation Research/Reviews in Mutation Research ·Claúdia Vitória de Moura Gallo,Gulnar Azevedo e Silva Mendonça,(unknown),Magali Olivier,Pierre Hainaut	21
20	The Tumor Suppressor Gene TP53: Implications for Cancer Management and Therapy 2004 ·Critical Reviews in Clinical Laboratory Sciences ·(unknown),Daniela Maurici,Magali Olivier,Claude Caron de Fromentel,Pierre Hainaut	31

About Magali Olivier

Magali Olivier is a scholar working on Cancer Research, Oncology and Biotechnology, having authored 68 papers that have together received 9.4k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (43 papers), Cancer Genomics and Diagnostics (25 papers) and Epigenetics and DNA Methylation (9 papers). The work is most often cited by research in Cancer Research (3.2k citations), Oncology (5.1k citations) and Molecular Biology (5.6k citations). Magali Olivier has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Pierre Hainaut, Monica Hollstein, Audrey Petitjean, Rosalind A. Eeles, Curtis C. Harris, Chikashi Ishioka, Shunsuke Kato, Sean V. Tavtigian, Maria Isabel Achatz and Ewy A. Mathé. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Nature reviews. Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact